Pharmaron Beijing (03759) released its interim results, showing a profit attributable to shareholders of 750 million yuan, an increase of 7% year-on-year.

Pharmaron Beijing (03759) announced its interim results for the six months ended June 30, 2026, during which the group achieved revenue of 7.595 billion RMB, an increase of 17.9% year-on-year; profit attributable to equity holders of the parent company was 750 million RMB, up 7% year-on-year; and basic earnings per share was 0.4138 RMB. The company continues to deepen its customer-centric service philosophy, relying on a fully integrated service platform while adhering to the highest international quality regulatory standards. It fully leverages the advantages of close collaboration among its teams in China, the UK, and the US to meet the diverse needs of global clients at various stages of research and development. In expanding its strategic customer base, the company has effectively tapped into customer needs, achieving significant results, particularly with large pharmaceutical clients. At the same time, the company continues to broaden its customer coverage and empowers clients' new drug development with cutting-edge technologies, maintaining an industry-leading position in the small molecule sector while also experiencing rapid development in new molecular type projects. Regarding the Chinese market, the company actively implements market strategies that better align with local conditions. With the acceleration of the internationalization process of innovative drugs in China, business with Chinese clients has seen rapid growth. In the first half of 2026, alongside the continuous expansion of strategic customers and the progression of CDMO service projects into later stages, the companys new signed orders increased by over 30% year-on-year. Based on new signed orders and business trends, the company expects its revenue for the entire year of 2026 to grow by 15% to 20% year-on-year.